AbbVie (ABBV) Capital Expenditures (2012 - 2026)

AbbVie (ABBV) has reported Capital Expenditures for 15 consecutive years, with $322.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Capital Expenditures rose 19.7% year-over-year to $322.0 million in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 24.23% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 24.64% from the prior year.
• Capital Expenditures was $322.0 million for Q2 2026 at AbbVie, up from $265.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $381.0 million in Q3 2025 and troughed at $143.0 million in Q2 2022.
• A 5-year average of $235.9 million and a median of $227.0 million in 2023 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures slipped 26.67% in 2022 and soared 53.01% in 2025, its largest moves.
• Over 5 years, Capital Expenditures stood at $213.0 million in 2022, then retreated by 3.76% to $205.0 million in 2023, then jumped by 41.95% to $291.0 million in 2024, then gained by 13.06% to $329.0 million in 2025, then dropped by 2.13% to $322.0 million in 2026.
• The last three Capital Expenditures figures came in at $322.0 million (Q2 2026), $265.0 million (Q1 2026), and $329.0 million (Q4 2025), per Business Quant data.